Efficacy and safety of an NRTI-sparing dual regimen of raltegravir and ritonavir-boosted protease inhibitor in a triple antiretroviral class-experienced population.

HIV clinical trials

Volumn 10, Issue 5, 2009, Pages 337-340

  Allavena, C ^a   Mounoury, O ^a   Rodallec, A ^a   Reliquet, V ^a   Billaud, E ^a   Raffi, F ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 PYRROLIDONE DERIVATIVE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR;

ADULT; AGED; COHORT ANALYSIS; DRUG COMBINATION; DRUG EFFECT; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MALE; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HIV; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; PYRROLIDINONES; RITONAVIR; TREATMENT OUTCOME;

EID: 75649108239     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct1005-337     Document Type: Letter

References (0)